Drug Trial Radar · NCT01146652
Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)
Last checked: Nov 20, 2026Latest source record: Mar 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,023
Actual
Start
Jun 21, 2010
Primary completion
Dec 31, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jun 17, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Main Study: Primary Objective: Assess the long term safety of sarilumab in participants with rheumatoid arthritis (RA). Secondary Objective: Assess the long term efficacy of sarilumab in participants with RA. Sub-Study: This phase 3, open label sub-study was aimed to assess the usability of PFS-S when used by participants with moderate or severe RA, or their professional or non-professional healthcare providers in an unsupervised real-world situation. To mimic the real-world practice, the sub-study was incorporated into the LTS11210 study without additional visits compared to the scheduled visits in the main study. The duration of this sub-study was 12 weeks.
Conditions
- Rheumatoid Arthritis
Interventions
SAR153191 (REGN88)Drug
Pharmaceutical form: solution Route of administration: subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From first dose (i.e., Day 1 of study LTS11210) up to 60 days after last dose (maximum duration: up to 523 weeks)
- Sub-study: Number of Participants Reported Product Technical Complaints (PTC), Product Technical Failures (PTF) and/or Failed Drug Deliveries (FDD) With Pre-filled Syringe With Safety SystemTime frame: From Week 24 to 36
- Sub-study: Number of Product Technical Complaints - Product Technical Failures With Pre-filled Syringe With Safety SystemTime frame: From Week 24 to 36
- Sub-study: Number of Failed Drug Deliveries Associated With Pre-filled Syringe With Safety SystemTime frame: From Week 24 to 36
- Sub-study: Number of Product Technical Complaints With Pre-filled Syringe With Safety SystemTime frame: From Week 24 to 36
Locations
335 sites in 40 countries. Site status is shown where the registry gives one.
Investigational Site Number 840070
Anniston, Alabama
Investigational Site Number 840138
Birmingham, Alabama
Investigational Site Number 840152
Huntsville, Alabama
Investigational Site Number 840072
Gilbert, Arizona
Investigational Site Number 840141
Glendale, Arizona
Investigational Site Number 840134
Fullerton, California
Investigational Site Number 840008
La Jolla, California
Investigational Site Number 840135
San Diego, California
Investigational Site Number 840021
Santa Maria, California
Investigational Site Number 840100
Stanford, California
Investigational Site Number 840049
Upland, California
Investigational Site Number 840151
Colorado Springs, Colorado
Investigational Site Number 840130
Lewes, Delaware
Investigational Site Number 840153
Aventura, Florida
Investigational Site Number 840050
Clearwater, Florida
Investigational Site Number 840033
Fort Lauderdale, Florida
Investigational Site Number 840041
Gainesville, Florida
Investigational Site Number 840067
Jupiter, Florida
Investigational Site Number 840048
Miami, Florida
Investigational Site Number 840024
Naples, Florida
Investigational Site Number 840006
Orlando, Florida
Investigational Site Number 840128
Ormond Beach, Florida
Investigational Site Number 840063
Palm Harbor, Florida
Investigational Site Number 840155
Palm Harbor, Florida
Investigational Site Number 840060
Sarasota, Florida
Investigational Site Number 840140
Tampa, Florida
Investigational Site Number 840126
Vero Beach, Florida
Investigational Site Number 840003
Atlanta, Georgia
Investigational Site Number 840028
Decatur, Georgia
Investigational Site Number 840027
Marietta, Georgia
Investigational Site Number 840018
Idaho Falls, Idaho
Investigational Site Number 840046
Chicago, Illinois
Investigational Site Number 840052
Kansas City, Kansas
Investigational Site Number 840230
Elizabethtown, Kentucky
Investigational Site Number 840015
Lexington, Kentucky
Investigational Site Number 840120
Baton Rouge, Louisiana
Investigational Site Number 840109
Lake Charles, Louisiana
Investigational Site Number 840055
Frederick, Maryland
Investigational Site Number 840013
Wheaton, Maryland
Investigational Site Number 840154
Boston, Massachusetts
Showing 40 of 335 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.